Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

OncoTherapy Science Inc lowers consolidated full-year forecast for FY 2014


Friday, 31 Jan 2014 03:00am EST 

OncoTherapy Science Inc:Sees revenue of 1,000 million yen for the fiscal year ending Mar. 31, 2014, compared to the previous forecast of 4,756 million yen.Sees operating profit of a loss of 3,500 million yen, compared to the previous forecast of 324 million yen.Sees ordinary profit of a loss of 3,500 million yen, compared to the previous forecast of 324 million yen.Sees net profit of a loss of 3,450 million yen, compared to the previous forecast of 271 million yen.Sees earnings per share of a loss of 26.46 yen, compared to the previous forecast of 2.51 yen.Says this is due to decreased sales.FY 2014 revenue of 5,410 million yen and net profit of 920 million yen - Thomson Reuters I/B/E/S. 

Company Quote

379.0
 --
17 Dec 2014